Oramed Pharmaceuticals Inc(ORMP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 1.16 | EPS (ttm) | 4.11 | Insider Own | 18.35% | Shs Outstand | 41.3M | Perf Week | -6.11% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | - | Insider Trans | -2.68% | Shs Float | 34.0M | Perf Month | 12% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | 0.43 | Inst Own | 40.48% | Short Float | 3.02% | Perf Quarter | 28.65% |
| Income | 0.17B | P/S | - | EPS this Y | 246.51% | Inst Trans | 12.86% | Short Ratio | 3.4 | Perf Half Y | 40% |
| Sales | 0.00B | P/B | 0.62 | EPS next 5Y | - | ROA | 65.52% | Short Interest | 1.03M | Perf YTD | 79.16% |
| Book/sh | 7.68 | P/C | 3.91 | EPS past 3/5Y | - | ROE | 73.75% | 52W High | -12.98% ($5.47) | Perf Year | 119.14% |
| Cash/sh | 1.22 | P/FCF | - | Sales past 3/5Y | -9.55% -5.9% | ROIC | 54.74% | 52W Low | 144.3% ($1.95) | Perf 3Y | 65.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 802.72% | Gross Margin | - | Volatility(W/M) | 4.65% 4.99% | Perf 5Y | -73.83% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | -31.37% |
| Dividend Ex-Date | 2026/1/16 | Quick Ratio | 4.98 | EPS Q/Q | 489.58% | Profit Margin | - | RSI (14) | 50.42 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.98 | Sales Q/Q | - | SMA20 | -2.36% ($4.88) | Beta | 1.28 | Target Price | $7 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/12 | SMA50 | 6.49% ($4.47) | Rel Volume | 0.44 | Prev Close | $4.78 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 541.86% - | SMA200 | 27.41% ($3.74) | Avg Volume(3M) | 0.30M | Price | $4.76 |
| IPO | 2004/3/19 | Option/Short | Yes/Yes | Trades | 1310 | Volume | 131,474 | Change | -0.42% |
Company
ORMP is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A clinical-stage biotech company developing oral insulin and oral obesity/diabetes peptide candidates based on oral protein drug delivery technology. The company focuses on technology that delivers insulin and peptides in pill form rather than by injection, is headquartered in the United States, and is conducting global clinical trials.
Over the past 1 year, on the higher side
13% below its 1-year high.
ORMP makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +246.5% this year.
Tap to view numbers
The stock looks undervalued
Trading at 1.2 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 1 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by +65.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 40.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
IWN 0.00%
DCOR 0.00%
DFAC 0.00%
DFAS 0.00%It ranks #4 in the industry
Based on market cap of $198M.
ORMP $198M PER 1.2
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is ORMP?
ORMP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ORMP?
The market cap of ORMP is approximately $198M, ranking 4,128 within its sector.
What is the P/E ratio of ORMP?
ORMP has a P/E ratio of approximately 1.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ORMP?
ORMP has recorded a 52-week high of $5.47 and a low of $1.95.
